The betibeglogene autotemcel (beti-cel) gene therapy caused paediatric and adult beta thalassaemia patients to achieve transfusion independence lasting over two years.
List view / Grid view
bluebird bio has chosen to suspend sales of Zynteglo while they investigate whether safety concerns identified with a related investigational gene therapy may apply to the licenced medicine.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.